Pancreatic cancer is a highly aggressive form of cancer with a five-year survival rate of only
ten percent. Pancreatic ductal adenocarcinoma (PDAC) accounts for ninety percent of those …

Pancreatic cancer (PC) poses significant clinical challenges, with late-stage diagnosis and
limited therapeutic options contributing to its dismal prognosis. A hallmark feature of PC is …

Background Survival from pancreatic cancer is low worldwide. In the US, the 5‐year relative
survival has been slightly higher for women, whites and younger patients than for their …

Background. Pancreatic ductal adenocarcinoma (PDAC) is a devastating cancer, and the
therapy options for PDAC remain restricted. The distinctive tumor immunological …

Pancreatic cancer (PC) is mainly derived from the exocrine pancreatic ductal epithelial cells,
and it is strongly aggressive malignant tumor. Due to its insidious onset and the lack of …

Patients bearing liver metastasis of pancreatic adeno carcinoma (PDAC) suffer from poor
prognosis due to its short duration and high mortality. Complex tumor microenvironment …

Purpose To investigate stem-related differentially expressed genes (DEGs) and their
potential mechanism in pancreatic cancer cells (MIAPaCa-2) exposed to x-ray and proton …

Background This retrospective study investigates factors affecting surgical and oncological
outcome after performing pancreaticoduodenectomy in octogenarian patients diagnosed …

Pancreatic cancer (PC) is mainly derived from the exocrine pancreatic ductal epithelial cells,
and it is strongly aggressive malignant tumor. Due to its insidious onset and the lack of …

Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate of all common solid
tumours. Novel therapeutics strategies are necessary to significantly improve patient …